Meeting Archive:
PPMD Webinar: DYSTANCE 51, a Phase 2/3 Clinical Trial of Investigational Suvodirsen in Duchenne

Meeting Description:
Suvodirsen (formerly known as WVE-210201) is an investigational stereopure oligonucleotide being developed as a potential treatment for boys with Duchenne muscular dystrophy with mutations amenable to exon 51 skipping. Wave Life Sciences is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating illnesses, such as Duchenne muscular dystrophy.
Wave has initiated DYSTANCE 51, a global phase 2/3 clinical trial evaluating the efficacy and safety of suvodirsen. Please join PPMD and Wave Life Sciences as we host an informational webinar Wednesday, October 16 at 1pm eastern to provide an overview of the suvodirsen program, including the DYSTANCE 51 Phase 2/3 clinical trial.
Please submit questions in advance to (subject line: Wave Webinar) by Monday, October 14 at 12pm eastern.
Date: Wed, Oct 16, 2019
Time: 01:00 PM EDT
Duration: 1 hour
Host(s): Parent Project Muscular Dystrophy
 Presenter Information
Moderator: Abby Bronson
Senior Vice President, Research Strategy
Parent Project Muscular Dystrophy

Michael A. Panzara, MD, MPH
Chief Medical Officer
Wave Life Sciences

Jeffrey Smith
Director, Patient Advocacy
Wave Life Sciences